Appoints Dmitri Kharkevitch as Vice President for Clinical Development
San Diego, CA, USA – December 10, 2015 –HUYA Bioscience International (HUYA) today announced the appointment of Dmitri Kharkevitch, M.D., Ph.D., as Vice President, Clinical Development Oncology. This most recent addition to the senior management team supports the Company’s expansion of its clinical development programs for the lead anti-cancer drug HBI-8000.
Dr. Kharkevitch has over 30 years of experience in oncology which includes 15 years in leadership positions within pharma and biotech covering clinical and medical affairs at Roche, Pfizer, Bristol-Myers Squibb, Vical, Antigenics and MD Anderson Cancer Center, Houston, TX.
Dr. Kharkevitch brings important experience in all phases of drug development for hematology and solid tumors. Moreover he has over 60 publications and patents that complement HUYA’s expertise in immuno-oncology. His international regulatory experience includes IND and NDA submissions to both the FDA and EMA
“Dr. Kharkevitch’s extensive experience in oncology clinical research and development comes at an important time for HUYA as we advance our lead oncology drug HBI-8000, a novel oral HDAC inhibitor with immunomodulatory properties, through clinical trials,” said Mireille Gillings Ph.D., CEO of HUYA. “We welcome him to the HUYA Senior Management team.”
Educated in Moscow, Russia Dr. Kharkevitch received his MD and PhD degrees from N.I. Pirogov Medical School and N.N.Blokhin Cancer Center.
About HUYA Bioscience International
HUYA is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations are established with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan, South Korea and eight strategic locations across China. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. HUYA was awarded the Asia-Pacific Stevie® Award in the Health Products and Services & Pharmaceuticals category and a Gold Stevie Award in the Woman of the Year 2015 American Business Award category. For more information, please visit www.huyabio.com